StockData

Spyre Therapeutics, Inc. (SYRE) shareholders

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$101.46+7.65 (+8.15%)

Close on Nov 18, 2026Market cap $8.95BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
96M of 88M shares
Institutional holders
265
91 new, 21 sold out
Net institutional buying
15M
In Q2 2026
Insider trades, 12 months
0 buys · 94 sales
Net sold $441.93M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Harwin Peter Evan
Joint filing with Kiselak Tomas (9.99%), Fairmount Funds Management LLC (9.19%) and 1 more
10,185,9619.99%13D (active) amendmentOct 7, 2026
Tomas Kiselak
Joint filing with Peter Evan Harwin (9.99%), Fairmount Funds Management LLC (9.15%) and 1 more
9,667,2019.99%13D (active) amendmentJun 23, 2026
Peter Harwin
Joint filing with Tomas Kiselak (9.99%), Fairmount Funds Management LLC (9.09%) and 1 more
9,016,7029.99%13D (active) amendmentApr 16, 2026
FMR LLC
Joint filing with Abigail P. Johnson (15.00%)
7,623,88115.00%13G (passive) amendmentNov 12, 2024
Senai Asefaw, M.D.
Joint filing with Paradigm BioCapital Advisors LP (5.10%), Paradigm BioCapital Advisors GP LLC (5.10%)
4,457,4505.10%13G (passive)Sep 24, 2026
Joseph Edelman
Joint filing with Perceptive Advisors LLC (5.00%), Perceptive Life Sciences Master Fund, Ltd. (5.00%)
4,319,4965.00%13G (passive)Apr 15, 2026
BlackRock, Inc.3,962,6356.60%13G (passive) amendmentJun 30, 2025
RTW Investments, LP
Joint filing with Roderick Wong, M.D. (6.20%)
3,621,9966.20%13G (passive) amendmentDec 31, 2024
Peter E. Deutsch3,550,2766.99%13G (passive)Oct 14, 2024
Tang Capital Management, LLC
Joint filing with Kevin Tang (5.30%)
3,200,0005.30%13G (passive)Apr 24, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SYREValueChange% of portfolio
FMR LLC13,026,18714.77%$1.16B+1,245,1630.05%
BlackRock, Inc.6,506,6057.38%$577.66M+985,3840.01%
Perceptive Advisors LLC4,319,4964.90%$383.48M+536,2715.76%
Rtw Investments, LP4,251,9964.82%$377.49M+80,0003.22%
Paradigm Biocapital Advisors LP3,840,7784.36%$340.98M+1,883,5126.38%
Vanguard Capital Management LLC3,448,6813.91%$306.17M+391,2800.01%
State Street Corp3,057,4163.47%$271.44M+450,3850.01%
VR Adviser, LLC2,985,4483.39%$265.05M−700,0008.04%
Price T Rowe Associates Inc /Md/2,960,8553.36%$262.87M+1,362,1250.03%
Driehaus Capital Management LLC2,799,1663.17%$248.51M+8,3811.44%
Geode Capital Management, LLC2,562,2652.91%$239.26M+841,3530.01%
Vanguard Portfolio Management LLC2,330,0982.64%$206.87M+1,744,9680.01%
Capital World Investors2,315,5532.63%$205.57M+1,648,9890.02%
Jupiter Topco LLC2,206,9362.50%$195.88MNew0.08%
TCG Crossover Management, LLC1,900,5822.16%$168.73M–4.06%
Tang Capital Management LLC1,892,2002.15%$167.99M–7.63%
Bank Of America Corp /De/1,777,8542.02%$157.84M+549,7610.01%
Adage Capital Partners Gp, L.L.C.1,722,3001.95%$152.91MNew0.21%
Wellington Management Group Llp1,581,5051.79%$140.41M−243,3060.02%
Goldman Sachs Group Inc1,478,0591.68%$131.22M+1,208,1210.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202626596M100.0%91 / 10456 / 2127M12M
Q1 202619883M94.0%58 / 6749 / 1112M7M
Q4 202515381M91.8%30 / 7627 / 1423M6M
Q3 202513765M73.2%22 / 4443 / 135M4M
Q2 202512964M72.2%18 / 6326 / 176M4M
Q1 202512962M70.4%20 / 5334 / 217M5M
Q4 202413160M67.9%34 / 6221 / 2113M5M
Q3 202411951M58.3%31 / 4224 / 1810M7M
Q2 202410751M57.8%29 / 4717 / 2321M2M
Q1 202410232M36.0%54 / 2015 / 69M5M
Q4 20235428M31.8%30 / 164 / 325M0M
Q3 2023273M3.7%27 / 00 / 03M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

280 funds held SYRE in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of SYREValue% of fundAs of
SMALLCAP World Fund Inc2,780,5363.15%$246.86M0.26%Jun 30, 2026
Fidelity Growth Company Fund2,576,9692.92%$189.41M0.19%May 31, 2026
Vanguard Total Stock Market Index Fund2,482,2982.82%$220.38M0.01%Jun 30, 2026
iShares Russell 2000 ETF1,911,6782.17%$169.72M0.20%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1,326,0351.50%$117.73M1.10%Jun 30, 2026
Vanguard Small-Cap Index Fund896,5591.02%$79.60M0.04%Jun 30, 2026
Vanguard Extended Market Index Fund886,1771.01%$78.67M0.08%Jun 30, 2026
Fidelity Advisor Biotechnology Fund857,3470.97%$84.30M3.83%Jul 31, 2026
Fidelity Small Cap Index Fund814,2900.92%$80.07M0.24%Jul 31, 2026
Fidelity Small Cap Growth Fund777,7200.88%$76.47M0.87%Jul 31, 2026
Select Health Care Portfolio760,0000.86%$55.86M0.97%May 31, 2026
Fidelity Growth Company K6 Fund749,6300.85%$55.10M0.20%May 31, 2026
T. Rowe Price Health Sciences Fund, Inc.711,8450.81%$63.20M0.53%Jun 30, 2026
iShares Russell 2000 Growth ETF687,5110.78%$61.04M0.40%Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.673,7990.76%$59.82M0.41%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Cameron TurtleChief Executive Officer, Director537,5400.61%Oct 2, 2026
Scott L. BurrowsChief Financial Officer79,7620.09%Oct 2, 2026
Heidy King-JonesSee Remarks2,8450.00%Oct 2, 2026
Sheldon SloanChief Medical Officer8,3340.01%Jul 2, 2026
Jeffrey W. AlbersDirector9,3600.01%Aug 10, 2026
Michael Thomas HendersonDirector68,6060.08%Jun 23, 2026
Healthcare Fund II L.P. FairmountDirector1,190,4971.35%Jun 23, 2026
Tomas KiselakDirector9,460,54010.73%Jun 23, 2026
Funds Management LLC FairmountDirector812,0760.92%Jun 23, 2026
Peter Evan HarwinDirector4,830,1775.48%Jun 23, 2026
Mark C. McKennaDirector––May 29, 2026
Laurie StelzerDirector––May 29, 2026
Sandra MilliganDirector––May 29, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Heidy King-Jones
See Remarks
Oct 1, 2026Sale(10b5-1 plan)−2,600$93.46$243.00K2,845
Heidy King-Jones
See Remarks
Oct 1, 2026Sale(10b5-1 plan)−2,100$92.70$194.67K5,445
Heidy King-Jones
See Remarks
Oct 1, 2026Sale(10b5-1 plan)−7,228$91.35$660.28K7,545
Heidy King-Jones
See Remarks
Oct 1, 2026Sale(10b5-1 plan)−16,605$90.35$1.50M14,773
Heidy King-Jones
See Remarks
Oct 1, 2026Sale(10b5-1 plan)−400$89.24$35.70K31,378
Heidy King-Jones
See Remarks
Oct 1, 2026Option exercise+28,933$14.50$419.53K31,778
Cameron Turtle
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−100$93.91$9.39K537,540
Cameron Turtle
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−4,990$93.37$465.92K537,640
Cameron Turtle
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−3,989$92.31$368.22K542,630
Cameron Turtle
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−2,638$91.49$241.35K546,619
Cameron Turtle
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−2,683$90.10$241.74K549,257
Cameron Turtle
Chief Executive Officer, Director
Oct 1, 2026Sale(10b5-1 plan)−600$89.14$53.48K551,940
Scott L. Burrows
Chief Financial Officer
Oct 1, 2026Sale(10b5-1 plan)−229$93.57$21.43K79,762
Scott L. Burrows
Chief Financial Officer
Oct 1, 2026Sale(10b5-1 plan)−3,071$92.95$285.45K79,991
Scott L. Burrows
Chief Financial Officer
Oct 1, 2026Sale(10b5-1 plan)−2,100$91.92$193.03K83,062
Scott L. Burrows
Chief Financial Officer
Oct 1, 2026Sale(10b5-1 plan)−1,500$90.27$135.41K85,162
Scott L. Burrows
Chief Financial Officer
Oct 1, 2026Sale(10b5-1 plan)−600$89.07$53.44K86,662
Scott L. Burrows
Chief Financial Officer
Oct 1, 2026Option exercise+7,500$14.50$108.75K87,262
Scott L. Burrows
Chief Financial Officer
Sep 30, 2026Sale(10b5-1 plan)−17,500$89.89$1.57M79,762
Scott L. Burrows
Chief Financial Officer
Sep 30, 2026Option exercise+17,500$14.50$253.75K97,262
Heidy King-Jones
See Remarks
Sep 2, 2026Option exercise+400$14.50$5.80K3,245
Heidy King-Jones
See Remarks
Sep 2, 2026Sale(10b5-1 plan)−400$90.00$36.00K2,845
Scott L. Burrows
Chief Financial Officer
Sep 2, 2026Sale(10b5-1 plan)−18,232$89.35$1.63M79,762
Heidy King-Jones
See Remarks
Sep 1, 2026Sale(10b5-1 plan)−400$89.38$35.75K2,845
Heidy King-Jones
See Remarks
Sep 1, 2026Sale(10b5-1 plan)−6,206$88.17$547.18K3,245
Heidy King-Jones
See Remarks
Sep 1, 2026Sale(10b5-1 plan)−16,548$87.20$1.44M9,451
Heidy King-Jones
See Remarks
Sep 1, 2026Sale(10b5-1 plan)−4,845$86.40$418.61K25,999
Heidy King-Jones
See Remarks
Sep 1, 2026Option exercise+27,999$14.50$405.99K30,844
Cameron Turtle
Chief Executive Officer, Director
Sep 1, 2026Sale(10b5-1 plan)−3,700$88.06$325.82K552,940
Cameron Turtle
Chief Executive Officer, Director
Sep 1, 2026Sale(10b5-1 plan)−400$89.07$35.63K552,540
Cameron Turtle
Chief Executive Officer, Director
Sep 1, 2026Sale(10b5-1 plan)−2,500$86.36$215.90K565,040
Cameron Turtle
Chief Executive Officer, Director
Sep 1, 2026Sale(10b5-1 plan)−8,400$87.15$732.06K556,640
Scott L. Burrows
Chief Financial Officer
Sep 1, 2026Option exercise+7,500$14.50$108.75K105,494
Scott L. Burrows
Chief Financial Officer
Sep 1, 2026Sale(10b5-1 plan)−4,384$87.11$381.89K100,210
Scott L. Burrows
Chief Financial Officer
Sep 1, 2026Sale(10b5-1 plan)−900$86.25$77.63K104,594
Scott L. Burrows
Chief Financial Officer
Sep 1, 2026Sale(10b5-1 plan)−2,016$88.03$177.47K98,194
Scott L. Burrows
Chief Financial Officer
Sep 1, 2026Sale(10b5-1 plan)−200$89.04$17.81K97,994
Jeffrey W. Albers
Director
Aug 7, 2026Sale(10b5-1 plan)−10,000$104.68$1.05M9,360
Jeffrey W. Albers
Director
Aug 7, 2026Sale(10b5-1 plan)−8,000$104.38$835.04K19,360
Jeffrey W. Albers
Director
Aug 7, 2026Sale(10b5-1 plan)−5,000$104.47$522.35K0
Jeffrey W. Albers
Director
Aug 7, 2026Option exercise+5,000$10.39$51.95K5,000
Cameron Turtle
Chief Executive Officer, Director
Aug 3, 2026Sale(10b5-1 plan)−16$97.46$1.56K567,540
Cameron Turtle
Chief Executive Officer, Director
Aug 3, 2026Sale(10b5-1 plan)−1,392$96.82$134.77K567,556
Cameron Turtle
Chief Executive Officer, Director
Aug 3, 2026Sale(10b5-1 plan)−5,635$95.93$540.57K568,948
Cameron Turtle
Chief Executive Officer, Director
Aug 3, 2026Sale(10b5-1 plan)−7,157$95.10$680.63K574,583
Cameron Turtle
Chief Executive Officer, Director
Aug 3, 2026Sale(10b5-1 plan)−800$93.97$75.18K581,740
Scott L. Burrows
Chief Financial Officer
Aug 3, 2026Sale(10b5-1 plan)−100$97.10$9.71K97,994
Scott L. Burrows
Chief Financial Officer
Aug 3, 2026Option exercise+7,500$14.50$108.75K105,494
Scott L. Burrows
Chief Financial Officer
Aug 3, 2026Sale(10b5-1 plan)−5,100$95.21$485.57K100,394
Scott L. Burrows
Chief Financial Officer
Aug 3, 2026Sale(10b5-1 plan)−2,300$96.30$221.49K98,094
Sheldon Sloan
Chief Medical Officer
Jul 1, 2026Option exercise+8,334$27.46$228.85K8,334
Sheldon Sloan
Chief Medical Officer
Jul 1, 2026Sale(10b5-1 plan)−6,500$87.52$568.88K1,834
Sheldon Sloan
Chief Medical Officer
Jul 1, 2026Sale(10b5-1 plan)−1,834$88.34$162.02K0
Scott L. Burrows
Chief Financial Officer
Jul 1, 2026Option exercise+7,500$14.50$108.75K105,494
Scott L. Burrows
Chief Financial Officer
Jul 1, 2026Sale(10b5-1 plan)−1,725$88.37$152.44K97,994
Scott L. Burrows
Chief Financial Officer
Jul 1, 2026Sale(10b5-1 plan)−5,775$87.55$505.60K99,719
Cameron Turtle
Chief Executive Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−10,176$87.44$889.79K587,364
Cameron Turtle
Chief Executive Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−590$88.91$52.46K582,540
Cameron Turtle
Chief Executive Officer, Director
Jul 1, 2026Sale(10b5-1 plan)−4,234$88.12$373.10K583,130
Scott L. Burrows
Chief Financial Officer
Jun 25, 2026Option exercise+15,000$14.50$217.50K112,994

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
16.54%
12M shares short
Days to cover
12.7
At 1M shares a day
Change since last report
-7.1%
From 13M shares
Short volume, 20 days
62.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Spyre Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 24,790 shares on Sep 10, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Heidy King-Jones
Officer
Oct 1, 202629,335$2.61MOct 1, 2026Exercise of Stock Options
Cameron Turtle
Director, Officer
Oct 1, 202645,000$4.01MOct 1, 2026Previously Exercised Stock Options
Scott L. Burrows
Officer
Sep 30, 202617,500$1.57MSep 30, 2026Stock Option Exercise
Heidy King-Jones
Officer
Sep 1, 202646,665$4.17MSep 1, 2026Exercise of Stock Options
Jeffrey W. Albers
Director
Aug 7, 20265,000$517.10KAug 7, 2026Exercise of Stock Options
Sessions, LLC
Director
Aug 7, 202618,000$1.86MAug 7, 2026Open Market Purchase
Scott L. Burrows
Officer
Aug 3, 202630,000$2.95MAug 3, 2026Exercise of Stock Options
Cameron Turtle
Director, Officer
Jul 1, 202645,000$4.00MJul 1, 2026Previously Exercised Stock Options
Scott L. Burrows
Officer
Jun 25, 202615,000$1.31MJun 25, 2026Stock Option Exercise
Healthcare Fund II L.P. Fairmount
Director
Jun 23, 20264,684,781$399.66MJun 23, 2026Acquired in reverse merger transaction
Michael Thomas Henderson
Director
Jun 22, 202620,000$1.77MJun 22, 2026Restricted Stock Units
Sheldon Sloan
Officer
Jun 3, 202616,667$1.15MJun 3, 2026Exercise of Stock Options
Michael Thomas Henderson
Director
May 8, 202680,000$5.85MMay 8, 2026Restricted Stock Units
Scott L. Burrows
Officer
May 1, 202627,500$2.05MMay 1, 2026Exercise of Stock Options
Sheldon Sloan
Officer
May 1, 202678,333$5.83MMay 1, 2026Exercise of Stock Options

See a number that looks wrong?